Introduction

Current approaches for gene therapy of human immunodeficiency virus type I (HIV-1) infection involve ex vivo transduction of CD4
+ T cells or CD34 + progenitor cells with Moloney murine leukemia virus (MoMLV)-based retroviruses expressing anti-HIV genes, followed by reinfusion of the altered cells into patients. This approach has shown to inhibit HIV replication in vitro and prolong T cell survival in vivo. [1] [2] [3] [4] [5] [6] [7] [8] The use of HIV-based conditionally replicating vectors expressing anti-HIV genes for the treatment of AIDS offers several theoretical advantages over the MoMLVbased vector systems. Unlike MoMLV, lentiviral vectors can effectively transduce both dividing and non-dividing cells such as resting T cells, macrophages or dendritic cells, 9, 10 which may play an important role in the maintenance of HIV-1 infection. 11, 12 In addition to the effect provided by the expression of an anti-HIV gene, these vectors can inhibit HIV-1 replication by sequestering the HIV-1 regulatory proteins Tat and Rev, by interfering with reverse transcription and/or by competing for packaging into HIV-1 encoded virions, facilitating the spread of the vector to unprotected cells in vivo. [13] [14] [15] [16] Transdominant negative mutants of Rev (TdRev) are one of the best inhibitory anti-HIV genes. [17] [18] [19] The consti- tutive expression of TdRev in an HIV-based vector packaging system is expected to inhibit the production of HIV-Gag-Pol encoded by the packaging plasmid, as well as the transport of unspliced vector genomic RNA to the cytoplasm, thus severely affecting vector titers. Numerous attempts have been reported to overcome the inhibitory effects of TdRev on vector production. For example, strategies have been developed to produce a Rev-independent lentiviral vector system by replacing the RRERev components with the Mason-Pfizer monkey virus (MPMV) or simian retrovirus type I (SRV-1) constitutive transport element (CTE) in the transfer vector and/or in the packaging helper plasmid. [20] [21] [22] [23] [24] [25] [26] [27] Although these modifications result in vectors less dependent on Rev, they are generally translated into a five-to 50-fold reduction in Gag-Pol synthesis and vector titers. Another approach to obtain Rev-independence is the introduction of silent mutations in the coding region of Gag-Pol in order to eliminate the instability sequences (INS) that are responsible for the Rev-dependent character of the mRNAs coding for Gag-Pol. [28] [29] [30] [31] [32] Using this Rev-independent version of Gag-Pol in combination with a Rev-dependent or with a Rev-independent transfer vector yielded titers of approximately 5 × 10 5 tu/ml and 1 x 10 5 tu/ml, respectively. 28 Titers similar to these ones are expected to be obtained when using this system to package Rev-independent HIV-based vectors constitutively expressing TdRev. In an alternative approach, we obtained similar titers by using a Rev-dependent packaging plasmid and overexpressing Rev during vector production. 27 Another possibility would be to express TdRev in a conditional and regulated fashion in such a way that its expression is suppressed in the packaging cell line, and becomes activated only in the target cell line.
In this report, we tested the latter possibility by constructing lentiviral vectors that express TdRev in the same exon/intron configuration as Rev is expressed and regulated in wild-type HIV-1. In this vector design, we preserved the Tat-Rev exons, the RRE-containing intron but mutated the second Rev exon sequences to encode TdRev. Further, overexpression of Rev provided by a second plasmid during packaging inhibits splicing of the Tat/TdRev intron, preventing the synthesis of TdRev. These vectors can be produced at higher titers than vectors that express TdRev in a constitutive fashion. They inhibit replication of laboratory and primary strains of HIV-1 in T cell lines and primary lymphocytes and reduce the infectivity of the virions that escape inhibition.
Results
Vector design
We sought to express TdRev in the context of a lentiviral vector, in such a way that its synthesis could be suppressed during vector production, but highly expressed in target cells. To this end we constructed the HIV-1-based vector pTRG (Figure 1 ). Compared with HIV-1, this vector contains a deletion of the gag-pol, vif, vpr and nef genes. It contains the central polypurine tract and central termination sequences (cPPT/CTS) that has been shown to improve vector titers and transduction efficiency. 25, 33, 34 It conserves the two tat and rev exons and the tat/rev intron in their native configuration, along with the necessary cis-acting sequences (splicing signals and RRE) to preserve its mode of splicing regulation by Rev. To produce TdRev, we altered the nucleotide sequence of the second Rev exon, such that four amino acids of the Rev C-terminal region are changed (LERLTL to DLRDTD), resulting in a transdominant negative Rev mutant protein. 18 In contrast to HIV-1 where Rev is negatively self-regulated, expression of TdRev in vector pTRG should not inhibit its own synthesis as TdRev does not prevent RNA splicing. As a final component of the pTRG vector, an EGFP gene (or Neo gene in later experiments) was inserted in the place of nef. The EGFP gene in this context serves as a traceable phenotypic marker to evaluate vector titers and can be used to monitor mobilization by wild type HIV-1. Figure 1b shows the expected pattern of alternatively spliced mRNAs and their expected encoded protein products for vector pTRG, according to the described HIV-1 splicing donor and acceptor sites. 35, 36 To add a second anti-HIV gene, we constructed vector pTRAG by introducing an env antisense sequence (envAS) within the Tat/TdRev intron of pTRG. This was done by flipping a 1.3 kb vpu-env fragment which does not contain any of the known elements necessary for regulation of intron splicing such as the RRE, splice donor and acceptor sites, polypyrimidine tract, intron branch point and exon-splice enhancer and silencer elements. 37, 38 As the envAS region is not present in the helper-packaging construct, the vector RNA is not expected to exert an antisense effect on the synthesis of Gag-Pol during vector packaging. In a target cell infected by HIV-1, where the expression of TdRev is not enough to completely block the function of Rev, and where a shift towards partially spliced and unspliced mRNAs may happen, formation of double-stranded mRNAs between the vector and virus mRNAs is supposed to trigger degradation of both mRNA products. Although this feature may reduce vector mobilization to secondary target cells, it is expected to increase inhibition of viral replication within transduced cells.
Rev inhibits TdRev expression
We first tested whether the overexpression of Rev was able to reduce the expression of TdRev encoded by vectors pTRG and pTRAG. As the expression of EGFP is expected to mirror the expression of TdRev we first measured the expression levels of EGFP in cells transiently transfected with each of the vectors plus increasing amounts of plasmid pCMVRev (Figure 2 ). The geometric mean of the EGFP fluorescence intensity in the EGFP + cell population decreased at increasing doses of the cotransfected plasmid pCMV-Rev. This was not due to an artifact of transfection or toxicity caused by expression of Rev as the percentage of viable GFP + cells was the same in all samples analyzed (Figure 2, dashed lines) . As an additional control we show that expression of EGFP from plasmid pHR-PGK-EGFP is not altered at increasing concentrations of pCMV-Rev. Therefore, expression of Rev reduces the expression of EGFP in vectors pTRG and pTRAG. We also tested whether expression of Rev could decrease the amount of cytoplasmic spliced mRNAs that code for TdRev (Figure 3a) . Plasmids pTRG or pTRAG were transiently cotransfected with increasing amounts of plasmid pCMVRev and cytoplasmic RNA was purified and analyzed by Northern blot using an EGFP probe. The identity of the RNA species observed in the Northern blot of Figure 3 is explained in the schematics of Figure 1 , (RNA B5 has the size of an unspliced full plasmid circle mRNA that is initiated and terminated at the 5' LTR due to inefficient polyadenylation at the 3'LTR). As expected, it can be observed that the hybridization intensity of the multiple spliced transcripts present in band B1 is reduced at increasing concentration of Rev. At the same time, the abundance of the partially spliced transcripts B3 and unspliced transcripts B4 and B5 increases at higher doses of Rev (Figure 3a and b) . The reason that RNA B2 is not regulated by Rev is not completely understood.
Finally, we tested the effect of Rev expression on TdRev protein levels by performing a Western blot on protein extracts obtained from 293T cells transiently transfected with plasmids pTRG or pTRAG and increasing amounts of plasmid pCMVRev (Figure 3c and d) . Although Rev and TdRev proteins are immunologically indistinguishable from each other with the polyclonal antibody used for detection, for unknown reasons, the Rev protein expressed from plasmid pCMVRev has a higher electrophoretic mobility than the purified recombinant Rev protein. The estimated molecular weight for TdRev and recombinant purified Rev was 22.5 kDa, while the estimated molecular weight of Rev produced by transfection of plasmid pCMVRev was 19.5 kDa. This allowed us to differentiate by Western blot the expression levels of Rev and TdRev. Figure 3c shows that cotransfecting 2 g of pCMVRev triggers a 10-fold reduction in the TdRev expression from pTRG, but only a two-fold reduction from pTRAG.
It is interesting to note that the effect of Rev on the expression of EGFP, the reduction of cytoplasmic spliced mRNA levels, the increase of the unspliced mRNA levels and the effect on TdRev protein synthesis was more pronounced for vector pTRG than for pTRAG. This may Gene Therapy indicate that flipping the env fragment in pTRAG may have affected the regulation of splicing of the Tat/TdRev intron by Rev, perhaps by abolishing some unknown splicing regulatory elements. In summary, these experiments demonstrate that overexpression of Rev during vector packaging leads to a reduced synthesis of TdRev.
Functional expression of TdRev
To test whether the TdRev protein expressed by these vectors maintained the transdominant negative properties, we measured the inhibition exerted by vectors pTRG and pTRAG on HIV-1 Gag-Pol synthesis. This was done in a one-step inhibition assay by transiently cotransfecting 2 g of each plasmid vector with 0.5 g of plasmid pNL4-3, which contains a full proviral copy of HIV-1 NL4-3 . 39 As negative control we used the plasmid pBluescript (pBSK, Stratagene, La Jolla, CA, USA). Figure 4 shows that transfection of a plasmid constitutively expressing TdRev (pSRD3 27 ) produces a 50% inhibition of p24 synthesis. A similar inhibitory effect is observed after transfecting a lentiviral vector backbone expressing a Neo gene (vector pcSN7 25 ). This inhibitory effect has been previously attributed to the sequestration of the regulatory proteins Tat and Rev that up-regulate the expression of Gag-Pol. 13 Cotransfection of vector pcSR7, 27 whose structure is similar to pcSN7 except that it expresses TdRev instead of Neo, produces a pronounced inhibition of p24 synthesis. Similarly, cotransfection of plasmids pTRG or pTRAG completely inhibited the synthesis of p24 encoded by the wild-type virus. The inhibitory effect attributed to either the expression of TdRev, sequestration of Rev or both can be partially reversed by cotransfection of 2 g of plasmid pCMV-Rev. Reversion of the inhibition by Rev was less for pSRD3 and pcSR7 than for pTRG or pTRAG. This suggests that the major cause for the reversion of inhibition may be due to suppression of TdRev expression by Rev, rather than titration of TdRev molecules by Rev. This experiment demonstrates that a strong transdominant negative effect on the synthesis of HIV-1 Gag-Pol is associated with vectors pTRG and pTRAG and suggests that expression of TdRev may account for the high level of inhibition observed on the synthesis of p24. It also shows that Rev synthesized by the HIV-1 NL4-3 provirus might not be sufficient to prevent the expression of TdRev from the vectors.
Vector production
In a previous work we showed that even in the absence of TdRev expression, overexpression of Rev leads to an increased synthesis of p24 encoded by the helper plasmid pCMV⌬R8.2. 27 To evaluate whether overexpression of Rev during packaging of vectors TRG and TRAG could be translated in increased vector titers, we performed a transient transfection of 8 g of plasmid pTRG or pTRAG with 8 g of helper plasmid pCMV⌬R8.2, 3.5 g of the VSV-G-encoding plasmid pLTR-G and with or without 5 g of plasmid pCMV-Rev. The lentiviral particles were collected in the supernatant 60 h after transfection and transduced into SupT1 cells. Figure 5 shows that expression of Rev during vector packaging leads to an eight-fold (P Ͻ 0.001) increase in the titers of both TRG and TRAG vectors, allowing titers of 2.5-4.0 × 10 5 tu/ml which were increased to 2 × 10 7 tu/ml by ultracentrifugation. The average p24 values obtained in these transfections was not significantly different for TRG or TRAG in 
Rev expressed from pCMVRev is the lower band. The electrophoretic mobility of TdRev expressed from pTRG and pTRAG is the same as the one observed from other plasmids expressing TdRev in a one exon configuration (pcSR9-3C, pcSR7) and for purified recombinant Rev protein (not shown). One of two experiments is shown. (d) The intensity of the bands for TdRev (solid symbols), Rev (open symbols) observed after transfection of pTRG (diamonds) or pTRAG (triangles) was measured by quantitative ECL and plotted against the amount of pCMVRev plasmid used in the transfection.
the presence of Rev (approximately 150 ng/ml), suggesting that the two-fold higher titers of TRG over TRAG might reflect the higher levels of TRG genomic RNA available for packaging (Figure 3b ). Similar titers of 2.5 × 10 5 cfu/ml were obtained with the analog vectors TRN and TRAN that contain a Neo selectable marker instead of the EGFP gene.
Challenge of transduced SupT1 cells with HIV-1
SupT1 cells were transduced with vectors TRG or TRAG (400 ng p24; MOI approximately 1.3), yielding unselected populations of SupT1/TRG and SupT1/TRAG cells that were 72% and 57% GFP + , respectively. Expression of TdRev protein was verified in these transduced populations of cells by Western blot (not shown). As negative controls we used SupT1 transduced with the MoMLV vector GC-SN DC or with the lentiviral vector HSN2. These control cell populations were selected for G418 resistance and therefore have an average of at least one vector copy per cell.
To test the degree of inhibition of HIV-1 replication conferred by these lentiviral vectors, we infected these cell populations with HIV-1 NL4-3 at MOIs of 0.1 and 0.01. Figure 6 shows that cells transduced with vectors TRG and TRAG delayed HIV-1 replication compared with the control transduced cells, even though only 72% and 57% of the cells in these two populations were transduced by these vectors, respectively. The control HIV-1-based vector HSN2 conferred no protection at MOI of 0.1 and only a limited protection at the MOI of 0.01. At MOI of 0.1 there was no difference between the protection conferred by vectors TRG or TRAG (Figure 6a) . At the lower MOI of 0.01 (Figure 6b ), vector TRAG showed better protection than vector TRG suggesting that the presence of the envAS sequence is conferring an additional anti-HIV effect.
When cells were infected with the more virulent (ie adapted for rapid growth and high yield in culture) HIV-1 MN-1 strain, all populations of cells suffered a rapid decrease in cell viability (50-90%) during the first 3 days after infection (Figure 7 ). To investigate whether the cells transduced by vectors TRG and TRAG had a preferential advantage for survival over the unengineered cells, we determined the percentage of GFP + cells present within the viable population of cells, during the challenge period ( Figure 7) . The percentage of GFP + cells in two independent cultures challenged with HIV-1 MN-1 increased from 72% and 57% to 97% and 82% for TRG and TRAG, respectively. It can be seen that the major increase in the percentage of GFP + cells within the viable population of Gene Therapy Finally, we wanted to evaluate the ability of these vectors to inhibit replication of HIV-1 primary isolates on primary T cells (Figure 8) . Peripheral blood mononuclear cells were depleted of CD8 + cells and stimulated for 2 days with anti-CD3 monoclonal antibody (OKT3) and IL-2. Cells (94% CD4 + ) were transduced with vectors TRG or TRAG (see Materials and methods), yielding 45% and 25% of GFP + cells, respectively. These cells were infected with three different primary isolates of HIV-1 (clade B, R5-tropic, non-syncitium inducing) at MOIs of approximately 0.005. Figure 8 shows that, in all cases, cells transduced with vectors TRG or TRAG significantly inhibited viral replication compared with the cells transduced with the negative control vector.
Figure 6 Inhibition of HIV-1 replication in SupT1 cells. 10 6 SupT1 cells transduced with vectors GC-SN DC (diamonds), HSN2 (triangles), TRG (squares) or TRAG (circles), and infected with HIV NL4-3 at the MOI of 0.1 (a), 0.01 (b). Virus replication was measured by reversed transcriptase (solid symbols, expressed in phosphorimager PSL units), and cell viability was measured by trypan blue exclusion every 5 days (open symbols and dashed lines).
Infectivity of viral particles that escape inhibition
To investigate whether HIV-1 viral particles released from transduced cells had reduced infectivity, naive SupT1 cells were infected with equal amounts of p24
Figure 8 Inhibition of replication of primary HIV-1 strains in PBMC transduced with vectors TRG and TRAG. PBMC cells transduced with vectors G1XSVNa (diamonds), TRG (squares) or TRAG (circles), were infected at MOI of approximately 0.005 with clade B, non-syncitium inducing primary HIV-1 isolates 92BR020 (a), 92US727 (b) and 92US714 (c). Virus replication was measured by p24 ELISA (Coulter).
obtained from SupT1/GC-SN DC , SupT1/HSN2, SupT1/TRG or SupT1/TRAG cells infected with HIV-1 NL4-3 . Different infections were set up using 100 or 20 ng of p24 from each supernatant. The kinetics of virus replication was followed for 19 days and evaluated by reverse transcriptase activity ( Figure 9) 
Discussion
Several reports have shown effective inhibition of HIV replication mediated by expression of TdRev in different cell types. 18, 19, [40] [41] [42] [43] [44] Clinical trials using transduced or transfected primary T cells have also shown a protective advantage for cells expressing TdRev. 5, 8 In these experi-
Figure 9 Infectivity of virions released from SupT1/TRG and SupT1/TRAG cells infected with HIV-1. 10 6 SupT1 cells were infected with the equivalent of 100 ng (a) or 20 ng (b) of p24 of supernatants obtained from SupT1 cells transduced with vectors GC-SN DC (diamonds), HSN2 (triangles), TRG (squares) or TRAG (circles) previously infected with HIV NL4-3 . The supernatants used for infection were collected at the initial phase of the productive infection, to ensure the collection of fresh virion particles. Wild-type virus replication was measured by reverse transcriptase assay (PSL units).
ments, TdRev was expressed in the context of MoMLVbased vectors, generally requiring high levels of TdRev expression, 41 and in most cases inhibition was reflected only by a transient delay in the onset of viral replication. We have tried to combine the inhibitory properties of an HIV-1-based vector backbone with the expression of the anti-HIV genes TdRev and envelope antisense RNA. To overcome the self-inhibition of vector production by expression of TdRev, we designed vectors where expression of this protein could be highly suppressed during vector packaging. In the target T cell, high levels of TdRev protein are predicted to build up before infection and block Rev protein function after infection by wild-type HIV-1.
Using this mode of regulation of TdRev expression, there is a complex balance of opposing regulatory forces taking place between Rev and TdRev in HIV-1-infected cells transduced by these vectors. The final outcome will likely be determined by the absolute levels of TdRev at the time of the infection and on the relative steady state rates of synthesis of TdRev from the vector and Rev from the virus, which will most likely depend on their relative genomic integration sites.
We demonstrated that expression of TdRev could be suppressed in these vectors by overexpressing Rev during vector packaging, resulting in 10-fold higher vector titers. Overexpression of Rev during packaging of vectors TRG and TRAG might lead to increased vector titers by several mechanisms (1) by stimulating the synthesis of p24 provided by the helper plasmid; (2) by blocking the synthesis of TdRev through splicing inhibition; (3) by titrating TdRev protein molecules; and (4) by increasing the amount of genomic vector mRNA available for packaging. The response of vector titers to Rev overexpression during vector packaging, is more marked in these kinds of vector than in the previous vectors that constitutively express TdRev. 27 Increased titer of vector TRG was translated in a higher fraction of protected cells than for vector TRAG. However, the inhibition of HIV-1 replication induced by vector TRAG was stronger than that conferred by TRG. This could be due to the additional inhibitory effects of the antisense sequences present in TRAG or due to the decreased regulatory response of TdRev to Rev displayed by this vector. An alternative explanation of the decreased protection against HIV-1 replication conferred by TRG compared with TRAG, might be due to the fact that TRG has an intact env gene, which upon Rev expression might be induced and contribute to the formation of syncitia, resulting in an increased cytopathic effect.
After transduction of primary T cells or a human T cell line, these vectors conferred increased protection against HIV-1 replication compared with mock-transduced cells or cells transduced with a lentiviral vector backbone. The potent inhibition of virus replication caused by these vectors is likely to be the result of several independent mechanisms. One of the most important contribution seems to be the expression of TdRev as the cotransfection of plasmids pTRG or pTRAG with pNL4-3 produces a complete inhibition in the synthesis of p24, and also because a similar vector backbone expressing Neo instead of TdRev does not confer a complete inhibition of HIV-1 replication. A second mechanism of inhibition might be caused by the sequestration of Tat and Rev by the TAR Gene Therapy and RRE sequences present in the vector backbone. This effect is consistent with the results seen in the transient cotransfection of pcSN7 with pNL4-3 plasmids (Figure 4) . However, results obtained by other authors have minimized the importance of the contribution of TAR and RRE decoys to the overall inhibition of HIV-1 replication by HIV-1-based vector backbones. 14, 15 A third possible mechanism is the competition of vector genomic RNA for packaging and its interference with reverse transcription in heterodimeric virions. This mechanism is predicted to decrease the infectivity of the outcoming virions, decreasing the rate of virus replication in unprotected populations of target cells. This effect was observed for vectors HSN2, TRG and TRAG in the experiments presented here (Figure 9 ).
Decreasing the infectivity of virions carrying a wildtype viral genome, as well as mobilization of the vector genome in virions synthesized by the wild-type virus is an important goal of these vectors as this can result in an increased fraction of protected cells in vivo (including the viral reservoirs), and in a slower progression of the disease. Reduction of virion infectivity is a unique property of lentiviral vectors that is not shared by previous MLV vectors expressing anti-HIV genes. Therefore, lentiviral vectors expressing anti-HIV genes reduce the rate of virus replication not only inside the protected cell, but also in secondary target cells. While the presence of a lentiviral vector backbone in the infected cells decreased the infectivity of the virions that escaped inhibition, this did not correlate with vector mobilization to secondary target cells. This observation is in contrast to what was observed by Bukovsky et al 15 using a lentiviral vector that does not express an anti-HIV gene. They observed high levels of vector mobilization to secondary target cells after infection with wild-type HIV-1 and attributed the inhibitory effect on HIV-1 replication to the mechanism of competition for packaging between the vector and viral RNAs. Data more analogous to the observations reported here were published by An et al. 14 In this report, a potent inhibition of HIV-1 replication was observed, using an HIV-1 construct containing null mutations in tat, rev, env and vpu (without any anti-HIV gene). This HIV-1-based vector was induced after co-infection with wildtype HIV-1 and the main mechanism of inhibition of HIV-1 replication has been suggested to be at the level of reverse transcription. In the experiments presented here, we see a reduction in infectivity of the escaped virions without significant vector mobilization. This again suggests that besides the competition for packaging into virions, reduction in infectivity is also taking place at a step before vector integration, possibly during reverse transcription.
It has been argued that the use of lentiviral vectors for clinical applications raises safety concerns due to the potential generation of pathogenic replication competent vectors. Efforts to reduce these concerns have focused on reducing viral sequences present in the vectors and by supplying trans-complementing genes on separate plasmids. For gene therapy of HIV-1-infected patients, the use of HIV-1-based vectors expressing anti-HIV genes should not raise such concerns as in the very unlikely and worst case scenario, multiple events of homologous recombination between virus and vector would generate a replication competent retrovirus at best identical to the wild-type virus. The vectors used in this paper are entirely derived from HIV-1 sequences and therefore there is no risk of introducing extraneous genes, such as heterologous promoters or RNA stabilizing elements, that would potentially generate a virus more pathogenic than the wild-type strains present in an HIV-1-infected patient.
Additional modifications to vector structure can be made to improve safety and efficacy. High levels of TdRev expression in target cells require transactivation of the LTR by Tat, a protein that has been implicated in causing apoptosis and immunosuppression of uninfected T cells. [45] [46] [47] Deletion of the second exon of Tat which mediates its binding to cellular integrins would prevent effects on bystander cells while still being able to carry out full transactivation of the LTR promoter. Additionally, deletion of env coding sequences from pTRG would avoid the toxic effects associated with env expression. 48 To increase efficacy, the incorporation of ribozymes and a mutant RRE that is not sensitive to TdRev 49 would allow construction of vectors with higher titers and higher inhibitory potential.
Compared with previous MLV vectors expressing TdRev or envelope antisense RNA, these new vectors provide similar levels of protection against HIV replication in the transduced cell, with the advantage that it can reduce the infectivity of the virus particles that escape inhibition, therefore limiting the overall spread of the virus in the untransduced population of cells. Compared with previous lentiviral vectors that express TdRev, these vectors can be produced at higher titers and have the advantage that they do not introduce extraneous sequences that could recombine into the wild-type virus, generating a potentially more pathogenic virus. Finally, this lentiviral vector design where the transgene is split in a two exon configuration with splicing regulated by Rev could potentially be adapted to express therapeutic or toxic proteins in the target cell line, while avoiding its expression in the packaging cell line.
Materials and methods
Plasmids
Plasmid pSRD3 encodes a transdominant negative mutant of Rev (TdRev), isolated by PCR from plasmid LR DLDD SN, 18 under the control of the SV40 promoter. 27 A PCR fragment that contains the mutations that converts Rev into TdRev was amplified from pSRD3 using primers 5'-CGATTCTAGAACGGATCCTGAGCA CTTAT-3' and 5'-GATTCTAGAATCGACTAT TCTTTAGCTCCTGAC-3', digested with XbaI and cloned into the XbaI restriction site of vector pLITMUS29-⌬BamHI to obtain plasmid pTRA10. Plasmid pLITMUS29-⌬BamHI was created by filling in the pLITMUS29 (New England Biolabs, Maine, NE, USA) BamHI restriction site. Plasmid pTRA30 was created by cloning a 2.8 kb AvrII-BamHI restriction fragment from pNL4-3 (nt 5662-8465) into the same restriction sites of pLITMUS28 (New England Biolabs). This HIV-1 fragment from pNL4-3 spans the Tat/Rev first exons and intron and part of the second Tat/Rev exon. Next, we created plasmid pTRA31 by adding the remaining TdRev exon sequences from pTRA10. This was done by cloning a BamHI-XhoI fragment from pTRA10 into pTRA30 digested with the same restriction enzymes. An antisense env fragment was created from pTRA31 by flipping a 1.29 kb BbsI (blunted)-BsaBI fragment contained within the Tat/Rev intron and ligating it back in the opposite orientation, to obtain plasmid pTRA32. The 3-kb AvrII-XhoI restriction fragments from pTRA31 and pTRA32 were cloned into the HIV-1 vector backbone pNL4 25 to obtain plasmids pTRA33 and pTRA34, respectively. Finally, an EGFP marker gene was cloned in place of the nef gene, by cloning a 770-bp NcoI-XhoI restriction fragment from pcCG7 25 into the same restriction sites of pTRA33 and pTRA34, to obtain plasmids pTRG and pTRAG, respectively. A neomycin resistance gene (Neo) was amplified from plasmid pcSN6 25 with primers 5'-GAGACATCATGAGGATCGTTTCGCATG-3' and 5'-TTGCTCCATGTTTTTCTAGGT CTCG-3', digested with BspHI and XhoI and cloned into pTRA33 or pTRA34 digested with NcoI and XhoI to yield plasmids pTRN and pTRAN, respectively.
Construction of plasmids pcSN7 and pcSR7 has been previously described. 25, 27 These plasmids are HIV- 53 (2 × 10 5 ) were plated on six-well poly-Dlysine-coated plates and transfected with 2 g of vector plasmid DNA, 0.5 g of pNL4-3 plasmid (vector/HIV molar ratio Ϸ 8), 0.5 g of the luciferase-encoding plasmid pGL3 (Promega, Madison, WI, USA), and 2 g of either carrier DNA or plasmid pCMV-Rev, using Superfect transfection reagent (Qiagen, Valencia, CA, USA). Cells were washed 3 h after transfection, and cultured for 48 h in DMEM/10% FCS. The amount of virus in the supernatant was determined by p24 antigen capture assay (Coulter, Hialeah, FL, USA) and was subsequently normalized to the transfection efficiency as determined by luciferase activity.
Vector production and DNA transfections Viral vectors were produced by transient transfection of 4 × 10 6 293T cells plated on poly-D-lysine-coated 100 mm dishes (Becton Dickinson, Mountain View, CA, USA). Cells were cultured in DMEM supplemented with 10% FCS, 2 mM glutamine and 100 g/ml penicillin in a 5% CO 2 incubator for 24 h. The culture medium was changed 4 h before transfection. The calcium phosphate DNA coprecipitation method was used to transfect a total of 25 g of plasmid DNA per dish: 8 g of transfer vector plasmid, 8 g of the packaging helper plasmid pCMV⌬R8.2, 4 g of pLTR-G and 5 g of pCMVRev. After 16 h, cells were washed three times with PBS, 10 ml of new medium was added and cells were incubated for another 48 h. Supernatants were harvested and filtered through 0.45 m-pore-size cellulose acetate filters. Viral preparations 429 were concentrated by ultracentrifugation at 50 000 g for 90 min, and resuspended in RPMI.
Northern blot analysis
Total cytoplasmic RNA was purified 24 h after transient transfection of 293T cells, following RNeasy protocols (Qiagen). RNA was electrophoresed on 1% agarose-0.66 M formaldehyde gel, transferred to Hybond N + membranes and hybridized with a radiolabelled EGFP DNA probe. After exposure, blots were stripped and hybridized with a human ␤-actin DNA probe. Quantification of the hybridization signals was performed by phosphorimaging (Fujifilm BAS-1500, running Image Gauge software).
Western blot of TdRev
Protein extracts were obtained from 293T cells transiently transfected with vectors pTRG or pTRAG plus different amounts of plasmid pCMVRev or from SupT1 transduced with vectors pTRG and pTRAG. These protein extracts were subjected to SDS-PAGE electrophoresis, and subsequent immunoblotting using a sheep anti-HIV Rev polyclonal antibody (dilution 1:5000, Fitzgerald, Concord, MA, USA) as a primary antibody and a polyclonal donkey anti-sheep IgG/HRPO as secondary antibody (dilution 1:10000, Bethyl Laboratories, Montgomery, TX, USA). Chemiluminescent detection was performed using ECL Plus detection reagents (Amersham-Pharmacia, Uppsala, Sweden) and quantificated using a luminescent image analyzer camera (Fujifilm LAS-1000). 10 ng of a purified recombinant HIV-1 Rev protein (Bachem, San Diego, CA, USA), as well as extracts from 293T cells transfected with pCMV-Rev were used as a positive controls.
Titer determination
Titer was determined by transducing 3 × 10 5 293T or SupT1 cells with 0.2 or 0.04 ml of filtered non-concentrated supernatants, for 12 h, in the presence of 8 g/ml polybrene and measuring by FACS the percentage of GFP + cells 72-96 h after transduction. Titer was estimated by using the formula T = GCD/V, where G is the fraction of GFP + cells; C is the number of plated cells; D is the dilution factor of the supernatant; and V is the volume of supernatant used for transduction.
Transduction of SupT1 and PBM cells
SupT1 cells (3 × 10 5 ) were transduced with concentrated supernatant (approximately 400 ng p24, MOI 1) of vectors TRG or TRAG. Transductions were performed in fibronectin-coated 12-well plates in the presence of 5 g/ml protamine sulfate, for 16 h. After one round of transduction, SupT1 cells were 78% and 56% GFP + for TRG and TRAG, respectively.
Peripheral blood mononuclear cells were obtained from normal donors by apheresis and subsequent FicollHypaque density gradient centrifugation. CD8 + cells were depleted by using magnetic beads coated with anti-CD8 antibody (Dynal, Oslo, Norway). Partially purified cells (Ͻ0.1% CD8 + , 15% CD4 + ) were activated for 2 days in AIM-V medium supplemented with 10% FCS, 100 ng/ml OKT-3 and 200 U/ml IL-2. After that, cells were grown in AIM-V medium supplemented with 10% FCS and 200 U/ml IL-2. Transduction was performed three times at 24-h intervals with 1000 ng p24 of lentiviral vecGene Therapy tors TRG or TRAG (MOI approximately 5), or with the control MoMLV vector G1XSVNA (10 6 cfu/ml, MOI approximately 5), in the presence of 5 g/ml protamine sulfate. Each transduction was performed on fibronectincoated plates followed by a 60-min centrifugation at 32°C. After the third transduction cells were >75% viable and > 92% CD4 + . The fraction of transduced primary lymphocytes was 46% and 27% for TRG and TRAG, respectively.
HIV-1 infection
HIV-1 laboratory strains NL4-3 (2.5 × 10 6 TCID 50 /ml), MN-1 (1 × 10 5 TCID 50 /ml) and primary HIV-1 isolates 92BR020 (1.9 × 10 4 TCID 50 /ml), 92US714 (1.1 × 10 4 TCID 50 /ml) and 92US727 (3.3 × 10 4 TCID 50 /ml) were obtained from the AIDS Research and Reference Reagent Program, NIAID, NIH. Transduced SupT1 cells (10 6 /4 ml RPMI/10% FCS plus 4 g/ml Polybrene) were infected in six-well plates with HIV NL4-3 at MOIs of 0.01 and 0.1 or with HIV MN-1 at MOI 0.02. After 4 h of incubation at 37°C, cells were washed with 10 ml of PBS, resuspended in 5 ml of RPMI/10% FCS and plated in six-well plates. Aliquots of culture medium (2 ml) were removed every 2 days and replaced with fresh medium. These aliquots were stored in 96-well plates at Ϫ80°C for subsequent reverse transcriptase (RT) assay. Transduced PBMC (10 6 cells/4 ml AIM-V medium) were infected with each of the primary HIV-1 isolates at MOIs of 0.005 for 4 h, in the presence of protamine sulfate 5 g/ml. After infection, cells were washed, resuspended in 3 ml of AIM-V/10 % FCS/200 U/ml IL-2 and distributed into three separate wells in 24-well plates at 3 × 10 5 cells/well. Aliquots of 200 l were collected every other day, and virus replication was measured by p24 ELISA (Coulter, Brea, CA, USA). Cell viability was determined by trypan blue exclusion every 5 days For reinfection of naive SupT1 cells with supernatants collected from the primary challenges, 2-ml aliquots of supernatants were frozen at Ϫ80°C, and a 200-l aliquot was saved for p24 analysis. After p24 determination, supernatants were filtered and diluted to achieve the same p24 concentration.
Reverse transcriptase assay
Five l of viral supernatant was incubated with 25 l of reaction mix (50 mM Tris-HCl pH 7.8, 7.5 mM KCl, 5 mM MgCl 2 , 5 g/ml 25 nt polyA RNA, 1.5 g/ml 8 mer oligo-dT and 3.3 M [P 32 ]-dTTP) for 2 h at 37°C. After incubation, aliquots of 10 l and 2 l of reaction products were spotted on to DE-81 anion exchange paper. The paper was washed five times with 1 × SSC, dried and incorporated radioactivity was measured by phosphorimaging (FUJIBAS 1500).
